Search clinical trials for: Venetoclax, Azacitidine

Total 1253 results

National Cancer Institute (NCI)

Completed

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Leukemia Cutis | Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Assistance Publique Hopitaux De Marseille

Unknown

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Myelodysplastic Syndromes | Myeloid Leukemia

France
National Cancer Institute (NCI)

Active, not recruiting

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)

Acute Myeloid Leukemia

Italy, Spain, Canada, Germany, Korea, Republic of, Japan, Australia, France, United States, Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Primary Myelofibrosis | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
Shanghai Tong Ren Hospital

Recruiting

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia (SAV)

AML, Adult

China
Kahr Medical

Recruiting

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Takeda

Active, not recruiting

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

Acute Myeloid Leukemia (AML)

United States, France, Italy, Poland, Canada
The Hospital for Sick Children

Completed

COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors (COZMOS)

Childhood Solid Tumor | Recurrent Childhood CNS Tumor | Ependymoma, Recurrent Childhood

United States, Canada, Australia
The University of Texas Health Science Center,...

Completed

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma (5-AZA)

Brain Tumor Recurrent

United States
Shenzhen Second People's Hospital

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

China
Anhui Provincial Hospital

Recruiting

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

Myelodysplastic Syndromes

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Celgene Corporation

Completed

A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

Solid Tumors | Virally Mediated Cancers and Liposarcoma

United States
M.D. Anderson Cancer Center

Recruiting

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0

United States
Faron Pharmaceuticals Ltd

Recruiting

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Relapsed/Refractory AML

United States, Finland
Shanghai Tong Ren Hospital

Recruiting

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results (AVS)

AML | MRD

China
Celgene

Terminated

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Leukemia, Myeloid

United States, France, Belgium, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1

United States
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Terminated

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
University of Oklahoma
Celgene Corporation

Terminated

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Antonio M Jimenez Jimenez
AbbVie

Not yet recruiting

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Acute Myeloid Leukemia

United States
Anhui Provincial Hospital

Recruiting

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

Acute Myelocytic Leukemia

China
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Celgene

Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome With Excess Blasts | IDH2 Gene Mutation | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome | Blasts 20-30 Percent of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Withdrawn

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
AbbVie
Genentech, Inc.

Active, not recruiting

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (Viale-a)

Acute Myeloid Leukemia (AML)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Norway, Poland, Portugal, Puerto Rico, Russian Federation, South... and more
AbbVie
Genentech, Inc.

Active, not recruiting

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Acute Myeloid Leukemia (AML)

China
AbbVie
Genentech, Inc.

Active, not recruiting

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Canada, France, Germany, Italy, United Kingdom
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Leukemia

United States
Beat AML, LLC

Recruiting

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Previously Untreated Acute Myeloid Leukemia

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute

Canada, United States, Poland, Switzerland, Germany
AbbVie

Completed

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Cancer | Acute Myeloid Leukemia (AML)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative Neoplasm

United States
National Cancer Institute (NCI)

Completed

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
Celyad Oncology SA

Withdrawn

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (EPITHINK)

Myelodysplastic Syndromes | AML, Adult
Universitätsklinikum Hamburg-Eppendorf

Completed

5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Germany
National Institute of Diabetes and Digestive and...

Completed

5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia

Beta Thalassemia

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML (HO171)

AML, Adult

Netherlands
M.D. Anderson Cancer Center
Celgene

Completed

Azacitidine and CAPOX in Metastatic Colorectal Cancer

Colorectal Cancer

United States
Virginia Commonwealth University
AbbVie

Withdrawn

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Relapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

AML

Mexico
ImmunoGen, Inc.
Jazz Pharmaceuticals

Active, not recruiting

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Germany, France, Spain, Italy, United Kingdom

Search clinical trials for: Venetoclax, Azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations